Additional Limited 50mg Nirsevimab (Beyfortus™) Now Available for Initial Orders

Dear VFC Provider,

The California VFC Program has received additional allocations of the 50mg formulation of nirsevimab. As a result, most VFC providers that have provided VFC vaccine to at least 3 young infants per month may now place an initial order of the 50mg formulation, based on prior VFC utilization of routine vaccines (hepatitis B vaccine birth doses at hospitals, first doses of pneumococcal conjugate vaccine for outpatient providers). Providers with lower historical usage of these vaccines are unable to submit a request for doses at this time, and their order line for nirsevimab will be grayed out. These limits and eligibility may be changed depending on available supply.

Our current allocation of the national supply of 100mg formulation for nirsevimab is too small to expand ordering for all VFC providers. As a result, 100 mg doses remain available for ordering only
by hospitals, Tribal Health Clinics, selected Federally Qualified Health Centers (FQHCs)/Rural Health Centers (RHCs) and Public Health Department Clinics. Expansion to additional VFC Providers will depend upon additional allocations to the California VFC Program.

BACKGROUND
On October 13, 2023, CDC paused ordering of nirsevimab for VFC programs in the US due to a shortage in supply. The shortage is expected to continue in both public and private sector supplies throughout the 2023-2024 RSV season. As a result, CDC is allocating both the 50mg and 100mg formulations to states, at an interval currently estimated at every 2 to 3 weeks. The California VFC Program re-opened ordering of nirsevimab on November 3 to limited provider types but is now expanding ordering of the 50mg formulation.

Nirsevimab is shipped nationally in units of 5 doses of either formulation. Supplies in the California VFC program are not yet sufficient to accommodate providers caring for smaller numbers of infants.

ORDER FREQUENCY
The VFC Program is expanding the opportunity to place initial requests of the limited allocations resulting from the shortage. If a practice has been approved for its initial order, additional requests will be denied. The feasibility of placing additional orders will depend upon the volume of future supplies. We will continue to provide timely updates on ordering to you.

RECOMMENDATIONS FOR USE OF NIRSEVIMAB
During the shortage, providers should not administer more than one 50 mg dose of nirsevimab to children indicated for a larger dose.
Additional recommendations are described in: Health Alert Network (HAN) - 00499 | Limited Availability of nirsevimab in the United States—Interim CDC Recommendations to Protect Infants from Respiratory Syncytial Virus (RSV) during the 2023–2024 Respiratory Virus Season

Thank you for your continued efforts and patience in these challenging circumstances.

RESOURCES

- CDC: RSV for Healthcare Providers
- CDC MMWR: Use of Nirsevimab for the Prevention of RSV Disease
- CDPH: RSV webpage
- AAP: Palivizumab Prophylaxis in Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection
- AAP: Nirsevimab Frequently Asked Questions

Thank you,

California Department of Public Health | Immunization Branch
Vaccines for Children (VFC) Program